Want to see BMY full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.6Last Year’s EPS
1.46Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted broad commercial momentum across the growth portfolio (9% growth) and several strong product performances (Eliquis +13%, Breyanzi +53%, Reblozyl +15%, Camzyos ~100%, Sotyktu +20%), along with multiple regulatory and clinical milestones (iberdomide priority review, positive mezignomide and ADC Phase III interim results) and a strong balance sheet (~$11B cash). Offsetting these positives were near-term headwinds including an 8% decline in Opdivo driven by wholesaler inventory dynamics, a 280 basis point gross margin decline due to product mix, continued generic pressures on legacy brands, and meaningful reliance on several late-2026 pivotal readouts that carry binary risk. On balance, the highlights materially outweigh the lowlights given diversified growth drivers, pipeline progress, reaffirmed guidance and financial flexibility, leading to a constructive outlook.Company Guidance
Total Revenue Growth
Total revenue for Q1 2026 was approximately $11.5 billion, up 1% year-over-year, with management indicating the business is tracking toward the upper end of full-year guidance.
Growth Portfolio Performance
Growth portfolio sales increased 9% year-over-year to $6.2 billion, driven by a broad set of assets (Reblozyl, Breyanzi, Opdualag, Qvantig, Cobenfy and others) and described as in line with expectations.
Eliquis Strength
Eliquis revenue was approximately $4.1 billion in the quarter, up 13% year-over-year, reflecting continued strong demand despite U.S. list price reduction dynamics.
Breyanzi Momentum
Breyanzi recorded strong adoption with first-quarter growth of 53%, cited as reflecting best-in-class profile and continued strong demand across approved indications.
Reblozyl and Sotyktu Growth
Reblozyl grew 15% year-over-year with uptake across MDS-associated anemia lines; Sotyktu global revenue grew 20% with recent approval expansion into psoriatic arthritis.
Camzyos Rapid Adoption
Camzyos revenue nearly doubled to $314 million in Q1, with patient starts and persistency described as strong and roughly 25,000 U.S. patients prescribed to date.
Qvantig Commercial Traction
Qvantig (subcutaneous product) achieved over 10% conversion from IV to the auto-injector in the U.S. in just over a year; management expects ~30%–40% conversion of IV business over the next two years.
Pipeline and Regulatory Milestones
Key R&D achievements in Q1 include FDA acceptance of the iberdomide filing with Breakthrough Therapy designation and priority review (PDUFA Aug 17), positive Phase III interim PFS for mezignomide (SUCCESSR-II), positive Phase III interim topline ADC results in TNBC (China), multiple approvals (including additional Opdivo indications) and several positive Phase I/II/III readouts across programs.
R&D Productivity and Cost Savings Targets
Company is investing in R&D infrastructure and AI with a target to identify lead molecules ~50% faster and to reduce cycle times ~30% versus a few years ago; remains on track to deliver the remaining $2.0 billion in cost savings from its strategic productivity initiative by end of 2027.
Strong Balance Sheet and Cash Generation
As of March 31, cash and marketable securities were approximately $11 billion and operating cash flow was about $1.1 billion in Q1, supporting capital allocation flexibility, business development and dividends.
BMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $56.95 | $59.91 | +5.21% |
Feb 05, 2026 | $56.40 | $58.25 | +3.30% |
Oct 30, 2025 | $41.21 | $44.13 | +7.09% |
Aug 01, 2025 | $41.33 | $42.20 | +2.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bristol-Myers Squibb Company (BMY) report earnings?
Bristol-Myers Squibb Company (BMY) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Bristol-Myers Squibb Company (BMY) earnings time?
Bristol-Myers Squibb Company (BMY) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BMY EPS forecast?
BMY EPS forecast for the fiscal quarter 2026 (Q2) is 1.6.
